DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Kashiwagi A, Shiga T, Akiyama N. et al.
Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT study).
Diabetol Int 2015;
6: 104-116
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.